Cargando…

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond

Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Andrew H., Roberts, Andrew W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256369/ https://www.ncbi.nlm.nih.gov/pubmed/37304937 http://dx.doi.org/10.1097/HS9.0000000000000912

Ejemplares similares

New Drugs Bringing New Challenges to AML: A Brief Review
por: Yeoh, Zhi Han, et al.
Publicado: (2021)

NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase
por: Kolawole, Oluwafunke R., et al.
Publicado: (2022)

Management of AML Beyond “3 + 7” in 2019
por: Canaani, Jonathan
Publicado: (2019)

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Beyond Kuhnian paradigms: Normal science and theory dependence in ecology
por: Layman, Craig A., et al.
Publicado: (2023)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and Beyond
por: Kouri, Fotini M., et al.
Publicado: (2012)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice
por: Anstee, Natasha S., et al.
Publicado: (2018)

Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics
por: haes, Inke De, et al.
Publicado: (2020)

Periodic fever syndromes: beyond the single gene paradigm
por: Westwell-Roper, Clara, et al.
Publicado: (2019)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

A novel polyethylene glycol (PEG)‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia (AML)
por: Ando, Hidenori, et al.
Publicado: (2021)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
por: Yamatani, Kotoko, et al.
Publicado: (2022)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
por: Madala, Hanumantha Rao, et al.
Publicado: (2018)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Heptahelical Receptor Signaling: Beyond the G Protein Paradigm
por: Hall, Randy A., et al.
Publicado: (1999)

CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020)

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
por: Halik, Adriane, et al.
Publicado: (2022)

Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.
por: Hatırnaz Ng, Özden, et al.
Publicado: (2022)

Prime, shock and kill: BCL-2 inhibition for HIV cure
por: Chandrasekar, Aswath P., et al.
Publicado: (2022)

Resveratrol Inhibition of Cellular Respiration: New Paradigm for an Old Mechanism
por: Madrigal-Perez, Luis Alberto, et al.
Publicado: (2016)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies
por: Tiribelli, Mario, et al.
Publicado: (2021)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
por: Molica, Matteo, et al.
Publicado: (2022)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

A new paradigm for the prediction of antidepressant treatment response
por: Leuchter, Andrew F., et al.
Publicado: (2009)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond
por: Keiffer, Gina, et al.
Publicado: (2020)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

Increasing Role of Targeted Immunotherapies in the Treatment of AML
por: Greiner, Jochen, et al.
Publicado: (2022)

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
por: Lanctôt, Krista L., et al.
Publicado: (2017)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lb132vujh134uhonvjaq0kv864